KDM2A and neoplasm: Dysregulation of histone methylation ‘writers’ and ‘erasers’ are closely linked to clinical outcomes in lung cancer patients through a variety of cellular pathways relating proliferation, invasion, EMT etc. Some histone methylation modifiers, such as SETD8, KDM2A and KDM6A, were identified as oncogenes or tumor suppressor genes in lung cancer [76, 105, 123]; some demonstrated potential link with drug resistance to lung cancer therapy, for example KDM5A and KDM3A [111, 117].